Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

Authors

Keywords

Journal

Volume 25, Issue 1, Pages 13-19

Publisher

Mary Ann Liebert Inc

Online

2010-03-01

DOI

10.1089/cbr.2009.0673

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started